News articles about Edap Tms (NASDAQ:EDAP) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Edap Tms earned a news impact score of 0.10 on Accern’s scale. Accern also assigned media headlines about the medical equipment provider an impact score of 46.151855077148 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- Global Tumor Ablation Market is expected to reach US$ 1,208.93 Mn with a CAGR of 13.2% from 2017 to 2025 – Acute Market Reports (digitaljournal.com)
- HC Wainwright Analysts Give Edap Tms S.A. (EDAP) a $7.00 Price Target (americanbankingnews.com)
- EDAP to Host Webcast Discussing HIFU Devices with an American … - GlobeNewswire (press release) (globenewswire.com)
- EDAP to Host Webcast Discussing HIFU Devices with an American Key Opinion Leader (finance.yahoo.com)
- AngioDynamics (ANGO) Shares Down Despite Q4 Earnings Beat (finance.yahoo.com)
Several equities research analysts have recently commented on EDAP shares. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Edap Tms in a report on Friday, April 7th. ValuEngine upgraded shares of Edap Tms from a “sell” rating to a “hold” rating in a report on Friday, May 19th. Finally, Zacks Investment Research upgraded shares of Edap Tms from a “strong sell” rating to a “hold” rating in a report on Thursday, May 18th.
Shares of Edap Tms (NASDAQ EDAP) traded up 0.96% on Thursday, hitting $3.15. 27,074 shares of the stock were exchanged. The company’s 50 day moving average is $3.24 and its 200-day moving average is $2.96. Edap Tms has a 52-week low of $2.25 and a 52-week high of $3.85. The stock has a market cap of $91.34 million, a PE ratio of 19.44 and a beta of 0.99.
Edap Tms (NASDAQ:EDAP) last released its quarterly earnings data on Wednesday, May 17th. The medical equipment provider reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.16. Edap Tms had a net margin of 11.95% and a return on equity of 27.90%. The company had revenue of $9.29 million for the quarter, compared to analysts’ expectations of $9.35 million. Analysts predict that Edap Tms will post $0.18 EPS for the current fiscal year.
WARNING: This piece was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://stocknewstimes.com/2017/07/20/edap-tms-nasdaqedap-receives-daily-news-impact-rating-of-0-10.html.
Edap Tms Company Profile
EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors.
Receive News & Ratings for Edap Tms S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms S.A. and related companies with MarketBeat.com's FREE daily email newsletter.
